Shuyi Ning , Yuanyuan Yao , Xinchi Feng , Yulin Tian
{"title":"Recent advances in developing bioorthogonally activatable photosensitizers for photodynamic therapy","authors":"Shuyi Ning , Yuanyuan Yao , Xinchi Feng , Yulin Tian","doi":"10.1016/j.ejmech.2025.117672","DOIUrl":null,"url":null,"abstract":"<div><div>Photodynamic therapy (PDT) is a promising and powerful cancer therapeutic modality, which can generate cytotoxic reactive oxygen species (ROS) from light-irradiated photosensitizers (PSs) to eradicate tumors. To overcome the drawbacks of currently used PSs, researchers have leveraged the advantages of bioorthogonal reactions to design diverse bioorthogonally activatable photosensitizers with excellent tumor selectivity, high ROS generation controllability, and low adverse effect for effective antitumor photodynamic therapy. In this review, we comprehensively summarize and highlight the recent advances in the development of bioorthogonally activatable photosensitizers, including the structure types, designing strategies, activation patterns, photophysical properties, ROS generation efficiency, <em>in vitro</em> and <em>in vivo</em> activities, biological applications, and limitations. We also provide directions and perspectives to address the therapeutic challenges of bioorthogonally activatable photosensitizers for promoting clinical applications. We believe that the principles summarized here will offer useful references for further development of next-generation advanced intelligent photosensitizers and related strategies to realize precise and efficient tumor treatment in the future.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"291 ","pages":"Article 117672"},"PeriodicalIF":6.0000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523425004374","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Photodynamic therapy (PDT) is a promising and powerful cancer therapeutic modality, which can generate cytotoxic reactive oxygen species (ROS) from light-irradiated photosensitizers (PSs) to eradicate tumors. To overcome the drawbacks of currently used PSs, researchers have leveraged the advantages of bioorthogonal reactions to design diverse bioorthogonally activatable photosensitizers with excellent tumor selectivity, high ROS generation controllability, and low adverse effect for effective antitumor photodynamic therapy. In this review, we comprehensively summarize and highlight the recent advances in the development of bioorthogonally activatable photosensitizers, including the structure types, designing strategies, activation patterns, photophysical properties, ROS generation efficiency, in vitro and in vivo activities, biological applications, and limitations. We also provide directions and perspectives to address the therapeutic challenges of bioorthogonally activatable photosensitizers for promoting clinical applications. We believe that the principles summarized here will offer useful references for further development of next-generation advanced intelligent photosensitizers and related strategies to realize precise and efficient tumor treatment in the future.
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.